Tax Conditions for Smoking
(AIM2 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how different tax proposals on tobacco and nicotine products affect purchasing habits. Researchers aim to determine if taxes can influence the amount and type of tobacco products people buy. Participants will experience several scenarios with varying taxes to observe changes in their choices. The trial seeks individuals who smoke at least 10 cigarettes a day and use other tobacco products less than once a week. Those interested in how taxes might change smoking habits may consider joining. As an unphased trial, this study offers a unique opportunity to contribute to understanding the impact of tax policies on smoking behavior.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that these tax conditions are safe for participants?
In a previous study, researchers found that higher cigarette taxes can change smoking behavior. Specifically, 36.1% of participants reported smoking less when taxes increased. This suggests that changing taxes might influence smoking habits, but there is no direct evidence that the tax changes themselves cause any health problems.
This trial examines how different tax proposals affect smoking habits, not a new drug or treatment. Therefore, there is no concern about the safety of a new medication. Instead, the goal is to understand if taxes can help reduce smoking.12345Why are researchers excited about this trial?
Researchers are excited about the "Tax Conditions for Smoking" trial because it explores an innovative approach to reducing smoking rates through fiscal measures. Unlike traditional smoking cessation methods like nicotine replacement therapies or medications such as varenicline and bupropion, this trial evaluates the impact of different tax conditions. By experimenting with how changes in cigarette taxation can influence smoking behavior, the trial seeks to uncover effective economic strategies for curbing smoking. This approach offers a new angle by leveraging economic incentives, potentially leading to more sustainable public health solutions.
What evidence suggests that this trial's tax conditions could be effective for reducing smoking?
Research has shown that raising taxes on tobacco products effectively reduces smoking rates. In this trial, participants in the "Tax Conditions" arm will encounter various tax scenarios to assess their impact on smoking behavior. Studies have found that when cigarette prices rise due to taxes, fewer people smoke, particularly teenagers and young adults. One study discovered that increasing cigarette taxes by one dollar lowered the number of adult smokers by 8%. Additionally, higher taxes increase the likelihood of people quitting smoking altogether. Overall, the evidence supports that increasing taxes on tobacco products can significantly reduce smoking.678910
Who Is on the Research Team?
Jeff Stein, PhD
Principal Investigator
Virginia Polytechnic Institute and State University
Are You a Good Fit for This Trial?
This trial is for individuals who are at least 21 years old, smoke a minimum of 10 cigarettes daily, and use other tobacco products less than weekly. It's not suitable for those who are pregnant or breastfeeding.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants complete a one-session study including consent and behavioral tasks, and make hypothetical purchases of tobacco products under different tax conditions
Follow-up
Participants are monitored for purchasing behavior and substitution patterns after exposure to tax conditions
What Are the Treatments Tested in This Trial?
Interventions
- Control Condition
- Tax Conditions
Find a Clinic Near You
Who Is Running the Clinical Trial?
Virginia Polytechnic Institute and State University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator